Navigation Links
Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence
Date:4/30/2008

SAN BRUNO, CA, April 30 C. diff-associated disease (CDAD), otherwise known as severe intestinal disease brought on by the Clostridium difficile (C. diff) pathogen, has been the subject of heightened concern in the medical community. A new report released this month by the federal Agency for Healthcare Research and Quality revealed a 200 percent increase in potentially fatal diarrheal infections in U.S. hospitals between 2000 and 2005. Additionally, the Association for Professionals in Infection Control and Epidemiology (APIC) is launching the first national prevalence study for C. diff beginning May 1.

According to Patricia Raymond, MD, FACP, FACG, a Chesapeake, Virginia-based gastroenterologist, associate professor of clinical medicine at Eastern Virginia Medical School and host of the soon-to-be-launched Your Health Choice radio program, traditional treatment for C. diff-associated disease is the use of powerful antibiotics such as metronidazole or vancomycin, but one of the most troublesome aspects of the disease is its high rate of recurrence. But studies show that adding the yeast-based probiotic Saccharomyces boulardii (sold under the brand name Florastor®), can cut the rate of recurrence by about half.

Almost one in four CDAD patients will experience a recurrence of symptoms after a round of antibiotic therapy alone, says Dr. Raymond. C. difficile colitis has been in the news recently as more virulent strains are emerging. These more toxic bugs lead to higher rates of surgery for colon removal and death from the infection. Doctors are using everything in their toolboxes to combat C. difficile, and one of our proven tools is Saccharomyces boulardii. When a relapse occurs, use of Florastor during the antibiotic course can help protect against future relapses.

A recent meta-analysis of 31 studies compiled and published in the American Journal of Gastroenterology concluded that S. boulardii is the only probiotic that is effective in fighting recurrent C. diff-associated disease1 Additionally, an article in the March 2006 issue of Gastroenterology and Hepatology showed that use of S. boulardii provided an almost 50 percent decrease in subsequent recurrence among patients who suffered recurrent CDAD symptoms.2 Because Florastor (S. boulardii) is a yeast and not a bacteria, it is not killed by the strong antibiotics that are being used to kill the C. diff bacteria, so it survives in the digestive tract, says Dr. Raymond. When the baby C. diff emerge from their spores, they are greeted by a well-colonized gut, rather than an empty playground.

CDAD is usually indicated by severe abdominal pain, diarrhea with mucous and blood passage, and fever. Dr. Raymond advises those exhibiting these symptoms to see a physician immediately to be tested for the presence of the C. diff toxins and to be prescribed proper antibiotics, since over-the-counter anti-diarrheal agents should be avoided.

Traditional OTC anti-diarrheal products actually slow down the speed of fluids moving through your bowels, and, in the case of C. diff, keeping the bacteria in the bowels is actually a bad thing, she adds.

Healthcare practitioners are advised to adhere to strict hand-washing policies in offices and hospitals to help prevent the spread of this and other types of bacteria.

Florastor has shown in more than 50 years of extensive international use to be safe and effective, with an estimated 1.7 billion daily doses sold to date. It is mentioned by the World Health Organization (WHO) for use in the management of C.diff-associated disease.3


'/>"/>

Contact: Christina Occhipinti
cocchipinti@robinleedyassociates.com
914-241-0086
Biocodex, Inc.
Source:Eurekalert

Related medicine news :

1. Garmin Reports Record First Quarter; Strong Margins and Increased Market Share
2. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
3. LMS CALM(R) receives high customer satisfaction scores in the 2008 KLAS Labor and Delivery report
4. BASF Podcast: The Chemical Reporter - Why do You Get Garlic Breath?
5. New Thomson Reuters Biomarkers Report Shines a Light on Revolutionary New Area of Drug Development
6. Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk)
7. Mindray to Report First Quarter 2008 Financial Results on May 7, 2008
8. Kensey Nash Reports Third Quarter Record Revenue and Sales
9. Webcast Alert: HCA announces HCA 1Q 2008 Earnings Report
10. Landauer, Inc. Reports Record Results for Second Quarter
11. Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... program today with a new Indiegogo campaign . Individuals are now able to ... the Los Angeles area, either as a participating patient or through an Indiegogo donation. ...
(Date:2/23/2017)... ... 2017 , ... Carlos Gutierrez has lived his spiritual life hardly ... which is the purpose of everyone in this universe. As Gutierrez sees the need ... Press) attempts to guide readers to expand one’s spiritual life. , “Our Spiritual Truths” ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy ... The technology is so cutting edge, in fact, the U.S. Food and Drug ... procedures. However, successful patient outcomes in certain clinical stem cell procedures have shown ...
(Date:2/22/2017)... ... February 22, 2017 , ... South Bend’s Lunkerville, the award-winning ... again feature Heroes On The Water (HOW), a non-profit organization dedicated to helping military ... has series host ‘Mike D’ traveling to Lake Denmark, New Jersey, to fish with ...
(Date:2/22/2017)... ... February 22, 2017 , ... A ... smaller and sometimes harder to reach ones, according to the results of a ... Stroke Conference in Houston by Ricardo A. Hanel, MD, PhD, neurovascular surgeon with ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Wash. and VANCOUVER, British Columbia ... (NASDAQ: OGXI ) today announced its year ... In January 2017, OncoGenex, and Achieve Life ... that they have entered into a definitive merger agreement ... transaction. Upon completion of the proposed merger, Achieve,s stockholders ...
(Date:2/23/2017)... , Feb. 22, 2017 Orthopedic and ... demand, as aging demographic patterns lead to an ... for sports- and exercise-related injuries, chronic back problems, ... lead sales gains. The future of medical implants ... the following questions and more: - What ...
(Date:2/23/2017)... , Feb. 22, 2017 Summary ... lymphoma partnering deals and agreements entered into by ... full report: http://www.reportlinker.com/p03605669-summary/view-report.html Description The ... 2010 report provides understanding and access to partnering ... leading healthcare companies. - Trends in ...
Breaking Medicine Technology: